DiagMetrics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

DiagMetrics is an innovative diagnostics company developing a proprietary Mask-Based Diagnostic (MBD™) platform that collects exhaled breath condensate (EBC) for non-invasive testing. With a strong intellectual property portfolio including multiple issued and pending patents, the company is initially targeting rapid screening for tuberculosis and respiratory viruses (SARS/Flu/RSV) using lateral flow assays and advanced biosensors. Backed by NIH RADx funding and a partnership with MilliporeSigma, DiagMetrics aims to democratize diagnostics by making testing as simple as breathing, with applications extending to chronic disease monitoring and oncology.

Infectious DiseaseRespiratoryOncologyChronic Disease

Technology Platform

Patented Mask-Based Diagnostic (MBD™) platform for non-invasive collection of exhaled breath condensate (EBC). The technology is adaptable to multiple detection formats, from low-cost lateral flow assays to multiplexed semiconductor biosensors, enabling testing for a wide range of respiratory and systemic biomarkers.

Opportunities

The massive, global need for simple, non-invasive TB screening in high-burden, resource-limited settings represents a clear first-market opportunity.

The platform's flexibility allows for rapid expansion into multiplex respiratory virus testing and, longer-term, into large markets like oncology screening and chronic disease monitoring, where frequent, non-invasive monitoring is highly desirable.

Risk Factors

Major risks include the unproven clinical validation of EBC for diagnostic use beyond research, the complex and uncertain regulatory pathway for a novel sample collection device, and significant competition from established diagnostic methods.

The company is also pre-revenue and will require substantial additional capital to reach commercialization.

Competitive Landscape

DiagMetrics operates in the emerging breath diagnostics space, competing with companies developing breathalyzer-style devices for volatile organic compound (VOC) analysis. Its unique differentiator is the mask-based collection of EBC (liquid), rather than gas, which may allow access to a different set of biomarkers. It faces intense competition from entrenched players using sputum, blood, and nasal swab samples for respiratory disease diagnosis.

More companies in Diagnostics & Precision Medicine →More companies in United States →